JPRN-UMIN000001267已完成2 期
Multicenter phase II trial of gemcitabine and S-1 for gallbladder cancer - Multicenter phase II trial of gemcitabine and S-1 for gallbladder cancer
agoya University Hospital0 个研究点目标入组 20 人开始时间: 2008年7月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria are as follows: active infection. pregnant or lactating women, women of childbearging age. the patient inappropriate for entry onto this study in the judgment of the investigator.
研究者
相似试验
已完成
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaJPRN-UMIN000021484Clinical study group of Osaka university, Hepato-Biliary- Pancreatic group100
已完成
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine in advanced biliary tract cancer (GS-COMBI).Advanced biliary tract cancerJPRN-UMIN000001703Japanese Endoscopist & IVRists group for Biliary Tract Cancer (JEIBIC)62
招募中
2 期
PDAC-GS/GA-rP2JPRN-jRCTs051180122Kobayashi Syogo100
招募中
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in patients with gemcitabine-refractory advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000007173Tokai University Hospital Kanagawa Cancer Center90
已完成
2 期
Phase II study of gemcitabine/S-1 combination therapy in patients with non-resectable advanced biliary tract cancernon-resectable biliary tract cancer or recurrent biliary tract cancer post surgical treatmentJPRN-UMIN000000792Kyoto University Hospital25